US Food and Drug Administration officials want user fees to fund more staff for the cell and gene therapy program.
The Center for Biologics Evaluation and Research wants additional support staff, as well as “indirect and direct review roles.” An...
CBER Proposes Increasing Cell, Gene Therapy Staff In PDUFA VII
Listen to this article
'Indirect and direct review roles' would be added with user fee funds after the PDUFA program is reauthorized.
Learn what's happening at the US FDA. On the go.
More from Cell & Gene Therapies
- • By
In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.
More from Advanced Technologies
- • By
Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.
- • By
Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.
